12 January 2023 | News
To leverage access to best-in-class diagnostic technologies for healthcare professionals especially oncologists
Photo Credit: Freepik
Singapore-headquartered Juniper Biologics has been granted distribution rights for Caris Life Sciences' molecular profiling services in South East Asia. The collaboration provides healthcare professionals the access to best-in-class diagnostic technologies that will enable them to make more precise and individualised treatment decisions for their cancer patients
Headquartered in the US, Caris has built the world's largest and most informative platform for analysing cancers with the most advanced and comprehensive tumour profiling available, which includes Whole Exome and Whole Transcriptome Sequencing across 22,000+ genes. Caris' suite of molecular profiling services provides oncologists with clinically important genomic information on key biomarkers and molecular signatures in oncology across all solid tumours.
Raman Singh, Juniper Biologics' CEO, said, "Through Caris molecular profiling, oncologists are able to recommend improved personalised treatments that specifically target a patients' cancer. This is a massive development in the advancing of cancer care options, many of which are antiquated and still failing patients. With this targeted approach, we collectively offer patients, especially those with rare or aggressive cancers, a real chance of recovery."
"Caris molecular profiling is the information bridge between tumor biology and cancer treatments, enabling the delivery of precision medicine by helping to illuminate a clearer path in personalized treatment selection for physicians and their patients. Our exclusive partnership with Caris Life Sciences to commercialise and distribute this service in South East Asia will make a real difference in empowering healthcare professionals to make the most informed decisions for their patients."